Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe 10mg Mounjaro KwikPen delivers tirzepatide as a fixed, pre-measured subcutaneous dose — there is no syringe to fill and no units to count manually. Each weekly injection from a 10mg pen releases exactly 10mg of tirzepatide in a set volume of fluid; the pen handles the measurement entirely. That said, understanding how the 10mg tirzepatide dosage in units relates to what you actually inject helps make sense of your treatment at this stage. As a prescription-only medicine, Mounjaro is dispensed and titrated under a prescriber's supervision — the pen and dose you use are determined through clinical assessment, not self-selection.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
When people ask about 10mg tirzepatide in units, they are usually drawing on experience with insulin, where 'units' refers to biological activity measured on a standardised international scale. Tirzepatide does not use that scale. Mounjaro doses are expressed in milligrams (mg) of tirzepatide per injection, and the KwikPen delivers that weight in a set volume of solution, the concentration is fixed at manufacture so that each depression of the pen releases the correct amount automatically.
The 10mg pen contains enough solution for four weekly injections, each pre-set to release 10mg. There is no dial to turn and no reading to take. If you have used an insulin pen before and are used to dialling a number of units, Mounjaro will feel very different: you simply attach a needle, prime, inject, and the dose is done. The Mounjaro treatment overview has more detail on how the KwikPen works in practice.
For readers curious about the volume side of this, our dedicated page on how 10mg tirzepatide relates to units covers useful context if you have ever seen the liquid described that way in a clinical setting. A related page also covers how many units 10mg tirzepatide represents in syringe terms.
A question our prescribers hear most weeks is whether reaching 10mg means treatment is nearly finished or nearly at its full dose. Neither, exactly. The UK licensed schedule for Mounjaro runs across six strengths: 2.5, 5, 7.5, 10, 12.5 and 15mg. Titration moves upward roughly every four weeks, though a prescriber may slow that pace if side effects are significant. [Source: NHS tirzepatide information page]
The 2.5mg starting dose exists to let your body adjust to a new mechanism, it is not a therapeutic weight-management dose in its own right. By the time you reach 10mg, your system has already moved through three previous doses. Some people find 10mg is their highest tolerated dose; others continue to 12.5mg or 15mg. The prescriber's job is to find the dose that balances effectiveness with tolerability for you specifically. Comparing the lower steps is straightforward: 5mg tirzepatide and 7.5mg tirzepatide follow the same pre-set pen logic.
Eligibility for tirzepatide under NICE guidance (TA1026) requires a BMI of 35 or above alongside at least one weight-related condition, though lower BMI thresholds can apply depending on ethnic background. Private prescribing through a regulated pharmacy follows the licensed SmPC criteria, which allows for adults with a BMI of 30 or above, or 27 with a relevant condition. A prescriber assesses the whole picture before any dose is approved. [Source: NICE TA1026, Recommendations chapter]
At 10mg, most people have been on Mounjaro for at least twelve weeks. The gastrointestinal side effects that are common early in treatment (nausea, loose stools, reduced appetite to the point of discomfort) often settle by this point, though they can return temporarily after a dose increase. That pattern is expected and does not necessarily mean 10mg is wrong for you; it usually eases within a couple of weeks.
Injection technique stays the same regardless of dose: abdomen, outer thigh or upper arm, rotating sites to avoid repeated use of the same spot. Storage remains refrigerated at 2–8°C. If you want a practical cost perspective on this stage of treatment, the Mounjaro price comparison page sets out how private pen costs vary by dose and provider in the UK. For a broader look at all weight-loss treatment options, the treatment overview is worth reading alongside this.
If you are transferring to a new pharmacy at this dose, or considering moving up to the next strength, a prescriber will want to review your progress and weight records before authorising the change. That clinical re-check is a safety step, not a formality. You can explore how nume handles this through the about us page or speak directly with the team via contact.
A few things are worth confirming with your prescriber as you use the 10mg pen. First, check that your injection technique has not drifted, subtle habits like always using the same spot or not letting the pen warm slightly before injecting can affect comfort. Second, if you are using oral contraception, the guidance for tirzepatide is to add a non-oral method for the first four weeks at each new dose level, because absorption of the pill may be temporarily affected; this applies at 10mg just as it did at earlier steps.
Third, keep monitoring how your body is responding, weight, appetite, any persistent side effects. This is the information your prescriber needs at review. Missed doses and timing questions are best addressed by reading your Patient Information Leaflet and raising anything unclear with the prescriber directly; the FAQs page covers common queries. If you are ready to discuss your next steps, speaking to our prescribers is the way to start.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.